

Ypsomed Holding AG  
Brunnmattstrasse 6  
PO Box  
3401 Burgdorf / Switzerland  
Tel. +41 34 424 41 11  
Fax +41 34 424 41 55  
[www.ypsomed.com](http://www.ypsomed.com)

---

## PRESS RELEASE

---

### **Issue price of Ypsomed shares set at CHF 68.00**

**The offering of shares in Ypsomed Holding AG attracted high investor interest and was 7.6 times covered. The issue price for one registered share in Ypsomed Holding AG was set at CHF 68.00. Shares will be trading on the SWX Swiss Exchange for the first time today.**

Burgdorf, 22 September 2004, 07:00 am – The offering period for shares in the Burgdorf-based medical technology supplier Ypsomed, the leading independent developer and manufacturer of custom-made injection pens for pharmaceutical and biotech companies and one of the leading suppliers of pen needles, ended yesterday. Following a bookbuilding process, the issue price was set at CHF 68.00 per registered share (nominal value of CHF 12.50), which is at the upper end of the originally defined price range of CHF 60.00 to CHF 68.00. The issue was 7.6 times covered at the issue price.

A total of 3,016,000 registered shares in Ypsomed Holding, stemming from a capital increase, were issued in connection with the IPO. This results in 11,016,000 registered shares in Ypsomed Holding AG outstanding after the listing. The free float will amount to 25.0%.

A delighted Willy Michel, Chairman of the Board of Directors of Ypsomed Holding AG, commented as follows: "The strong demand reflects the huge interest of both institutional and private investors in Ypsomed shares. I view this as a sign of investors' confidence in the continued growth of the Ypsomed Group."

Credit Suisse First Boston was acting as global coordinator and bookrunner for the offering, with Bank Sarasin & Co. Ltd, Berner Kantonalbank and Lombard Odier Darier Hentsch acting as co-managers.

Further information is available from Daniel Kusio, Head of Investor & Public Relations at Ypsomed Holding AG. Tel. +41 34 424 41 43 or Tel. +41 34 424 41 11.

This press release and further documents are available in electronic form at [www.ypsomed.com](http://www.ypsomed.com).

### **About Ypsomed**

Operating in the field of medical technology, Ypsomed is the leading independent manufacturer of injection pens for pharmaceutical and biotech companies, as well as one of the leading suppliers of pen needles. Currently enjoying dynamic growth, Ypsomed can draw on over 15 years' experience and is well-known for the consistently high quality, safety and reliability of its products, as well as its proven expertise in the area of diabetes. Thanks to a broad-based technology platform and some 100 patents, Ypsomed is widely regarded as the technology and innovation leader in this industry.

Ypsomed's core business consists of developing and marketing products and services allowing patients to administer their own medication in a safe, simple way. Our custom-made injection pens range from simple disposable pens to pens with variable dosing and electronic display through to highly complex injectors with multifunctional electronics. We are constantly expanding our core technology in the pen sector, e.g. with auto-injectors or motor-driven pens. Ypsomed also manufactures compatible pen needles with unique click-on function for both its own and all other widely available pens. As a distributor of pen needles in the major European markets, Ypsomed is in direct contact with patients, doctors and diabetes consultants.

### **Information on market and industry trends**

Innovative devices and systems enabling patients to inject drugs themselves (Medical Selfcare Solutions) are increasingly popular because they make a big contribution to ensuring therapeutic success whilst at the same time improving the patient's quality of life. Injection pens are simple to use, less painful and psychologically better accepted than traditional syringes. Straightforward, user-friendly appliances facilitate correct handling by patients, which in turn results in higher success rates. Injection systems therefore represent a key success factor for pharmaceutical and biotech companies. In an increasingly competitive environment, they also provide companies with an important marketing instrument for differentiating their own drugs from those of their competitors.

Injection therapies are therefore continually being extended to new areas. Diabetes is currently the main application, but other existing uses or likely candidates for injection treatments with devices include anaemia, hepatitis, hormone therapies, infertility, osteoporosis, psoriasis, rheumatoid arthritis, thrombosis and growth disorders. An ageing population also means additional growth in the total market. Moreover, pharmaceutical and biotech companies have numerous substances in their pipelines which will provide promising new treatments (some of which will have unique new modes of action) for serious illnesses, thereby significantly improving the quality of life enjoyed by those concerned. Many of these new drugs are manufactured using biotechnological methods and have to be injected because of their large chemical structure, and demand for custom made injection systems is set to grow.

### **Information about diabetes**

Diabetes Mellitus – more commonly known simply as diabetes – is a chronic disorder of the metabolism which occurs in two forms (type 1 and type 2). Diabetes is treated with various insulins. Ypsomed concentrates on type 2 diabetes, the form that affects around 90% of all diabetes patients. Together with lack of exercise, obesity is one of the main reasons for the increased incidence of diabetes. Experts estimate that occurrence of diabetes is growing at a rate of about 10% a year. The World Health Organization (WHO) predicts there will be some 300 million diabetics worldwide by the year 2025.

---

Important note:

"THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES. IN ADDITION, THE SECURITIES OF YPSOMED HOLDING AG HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT FROM REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS."